Enabling Warp Speed Using the Hypervelocity Innovation Model: A Blue Print for Drug Development in Pandemics

Pharmaceutical R&D is organized around prioritized investments, delivering on assets with the greatest return of investments. Linear sequencing of trials and financial risks are determinants of speed in an enterprise. There is less flexibility in leveraging expertise around priorities that are thrust on the system by external forces. This commentary provides an insight into enabling warp speed using a hypervelocity mindset for mobilizing resources and scientific creativity, for accelerated timelines in response to pandemics….

Author(s): Rajesh Krishna

Year: September 24, 2020

Back to top